Joseph Manko - Safeguard Scientifics Independent Director
| SFEDelisted Stock | USD 0.46 0.19 29.23% |
Director
Mr. Joseph M. Manko, Jr. is Independent Director of the Company. He is the Senior Principal of The Horton Fund, an investment management firm. Previously, Mr. Manko served as the Chief Executive Officer of Switzerlandbased BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds and the firms Special Situations and EventDriven strategies . Mr. Manko was a Managing Director and Head of Equity Capital Markets with Deutsche Bank in London and a Vice President at Merrill Lynch in Hong Kong . He began his career as a Corporationrationrate Finance Attorney at Skadden, Arps, in Los Angeles . Mr. Manko currently serves on the Board of Directors of RMS Medical Products Inc., a leading developer and manufacturer of medical devices and supplies, and Creative Realties, Inc, a marketing technology company . Mr. Manko has also served on the Board of Directors of several European biotechnology companies, including NovImmune, S.A. since 2019.
| Age | 55 |
| Tenure | 5 years |
| Phone | 610-293-0600 |
| Web | https://www.safeguard.com |
Safeguard Scientifics Management Efficiency
The company has Return on Asset of (0.0778) % which means that on every $100 spent on assets, it lost $0.0778. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2938) %, meaning that it generated no profit with money invested by stockholders. Safeguard Scientifics' management efficiency ratios could be used to measure how well Safeguard Scientifics manages its routine affairs as well as how well it operates its assets and liabilities.The company has 1.68 M in debt with debt to equity (D/E) ratio of 0.04, which may show that the company is not taking advantage of profits from borrowing. Safeguard Scientifics has a current ratio of 18.08, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Safeguard Scientifics until it has trouble settling it off, either with new capital or with free cash flow. So, Safeguard Scientifics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Safeguard Scientifics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Safeguard to invest in growth at high rates of return. When we think about Safeguard Scientifics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Catrambone | DWS Municipal Income | N/A | |
| Robert Wadsworth | Central Europe Russia | 76 | |
| William Adams | Nuveen New Jersey | 61 | |
| Perry Dellelce | Mount Logan Capital | N/A | |
| Leslie Gelb | Western Asset High | 80 | |
| Paola Mungo | Azimut Holding SpA | 48 | |
| Leo Blackford | Central Securities | 64 | |
| William Hutchinson | Western Asset High | 78 | |
| Donald Calder | Central Securities | 81 | |
| Friedbert Malt | Central Europe Russia | 73 | |
| Teresa Nicolini | Azimut Holding SpA | 65 | |
| Carter Walker | Central Securities | 81 | |
| Robert Agdern | Western Asset High | 70 | |
| David Shaw | Fiera Capital | 63 | |
| Raffaella Pagani | Azimut Holding SpA | 45 | |
| Alessandro Zambotti | Azimut Holding SpA | 35 | |
| Conrad Ciccotello | Tortoise Mlp Closed | 60 | |
| Richard Goeltz | Central Europe Russia | 71 | |
| Jay Inglis | Central Securities | 84 | |
| Charles Heath | Tortoise Mlp Closed | 75 | |
| David Kundert | Nuveen New Jersey | 76 | |
Management Performance
| Return On Equity | -0.29 | |||
| Return On Asset | -0.0778 |
Safeguard Scientifics Leadership Team
Elected by the shareholders, the Safeguard Scientifics' board of directors comprises two types of representatives: Safeguard Scientifics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Safeguard. The board's role is to monitor Safeguard Scientifics' management team and ensure that shareholders' interests are well served. Safeguard Scientifics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Safeguard Scientifics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Dobson, Independent Director | ||
| Ira Lubert, Independent Director | ||
| Russell Glass, Independent Director | ||
| Matthew Barnard, Secretary Counsel | ||
| Mark Herndon, Chief Financial Officer, Senior Vice President | ||
| Mark Dow, CFO CEO | ||
| David Kille, CFO | ||
| Alex Fuiks, Associate | ||
| Maureen Morrison, Independent Director | ||
| Albert II, Sr. VP and Managing Director of Healthcare | ||
| Scott Snyder, Senior Vice President Managing Director, Chief Technology and Innovation Officer | ||
| George MacKenzie, Independent Director | ||
| Jack Messman, Independent Director | ||
| John Shave, Vice President - Business Development and Corporate Communications | ||
| Eric Salzman, Chief Restructuring Officer | ||
| Stephen Zarrilli, President CEO, Director | ||
| Jeffrey McGroarty, CFO, Senior Vice President - Finance | ||
| Mark CPA, VP CFO | ||
| John Roberts, Independent Director | ||
| Robert Rosenthal, Executive Chairman of the Board, Principal Executive Officer | ||
| Stephen Fisher, Independent Director | ||
| Andrew Lietz, Independent Chairman of the Board | ||
| Seth Zuckerman, Associate Healthcare | ||
| Brian Sisko, Executive Vice President Managing Director | ||
| Mara Aspinall, Director | ||
| Joseph Manko, Independent Director |
Safeguard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Safeguard Scientifics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | |||
| Return On Asset | -0.0778 | |||
| Current Valuation | (4.6 M) | |||
| Shares Outstanding | 16.58 M | |||
| Shares Owned By Insiders | 28.01 % | |||
| Shares Owned By Institutions | 45.02 % | |||
| Number Of Shares Shorted | 208.05 K | |||
| Price To Earning | 23.06 X | |||
| Price To Book | 0.41 X | |||
| EBITDA | (7.36 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Safeguard Scientifics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Safeguard Scientifics' short interest history, or implied volatility extrapolated from Safeguard Scientifics options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Safeguard Scientifics information on this page should be used as a complementary analysis to other Safeguard Scientifics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Safeguard Stock
If you are still planning to invest in Safeguard Scientifics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Safeguard Scientifics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |